JPH0272893A - モノクローナル抗体、その製法およびそれを用いた癌疾患のスクリーニング方法 - Google Patents
モノクローナル抗体、その製法およびそれを用いた癌疾患のスクリーニング方法Info
- Publication number
- JPH0272893A JPH0272893A JP63202787A JP20278788A JPH0272893A JP H0272893 A JPH0272893 A JP H0272893A JP 63202787 A JP63202787 A JP 63202787A JP 20278788 A JP20278788 A JP 20278788A JP H0272893 A JPH0272893 A JP H0272893A
- Authority
- JP
- Japan
- Prior art keywords
- human
- cells
- cell line
- monoclonal antibody
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 44
- 201000011510 cancer Diseases 0.000 title claims abstract description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 17
- 238000012216 screening Methods 0.000 title claims description 12
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 210000004027 cell Anatomy 0.000 claims abstract description 70
- 238000000034 method Methods 0.000 claims description 27
- 239000000427 antigen Substances 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 210000004976 peripheral blood cell Anatomy 0.000 claims description 21
- 230000004927 fusion Effects 0.000 claims description 15
- 210000004698 lymphocyte Anatomy 0.000 claims description 7
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 5
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 102000016605 B-Cell Activating Factor Human genes 0.000 claims description 3
- 108010028006 B-Cell Activating Factor Proteins 0.000 claims description 3
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 2
- 101710186708 Agglutinin Proteins 0.000 claims description 2
- 208000004736 B-Cell Leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 108010062580 Concanavalin A Proteins 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- 101710146024 Horcolin Proteins 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 101710189395 Lectin Proteins 0.000 claims description 2
- 206010024305 Leukaemia monocytic Diseases 0.000 claims description 2
- 101710179758 Mannose-specific lectin Proteins 0.000 claims description 2
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 claims description 2
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims description 2
- 241000191967 Staphylococcus aureus Species 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000000389 T-cell leukemia Diseases 0.000 claims description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 239000000910 agglutinin Substances 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 210000003743 erythrocyte Anatomy 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 210000003714 granulocyte Anatomy 0.000 claims description 2
- 210000003494 hepatocyte Anatomy 0.000 claims description 2
- 230000000984 immunochemical effect Effects 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 239000003226 mitogen Substances 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 201000006894 monocytic leukemia Diseases 0.000 claims description 2
- 210000005087 mononuclear cell Anatomy 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 235000015277 pork Nutrition 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 1
- 230000007651 self-proliferation Effects 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 abstract description 13
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 abstract description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 abstract description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract description 4
- 201000000050 myeloid neoplasm Diseases 0.000 abstract description 4
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 abstract 3
- 208000035771 Malignant Sertoli-Leydig cell tumor of the ovary Diseases 0.000 abstract 2
- 206010030113 Oedema Diseases 0.000 abstract 2
- 230000003187 abdominal effect Effects 0.000 abstract 2
- 208000012221 ovarian Sertoli-Leydig cell tumor Diseases 0.000 abstract 2
- 201000009365 Thymic carcinoma Diseases 0.000 abstract 1
- 210000000683 abdominal cavity Anatomy 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 abstract 1
- 210000004989 spleen cell Anatomy 0.000 abstract 1
- 208000008732 thymoma Diseases 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 10
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 206010003445 Ascites Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 230000007910 cell fusion Effects 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 description 4
- 229940044173 iodine-125 Drugs 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 108010023244 Lactoperoxidase Proteins 0.000 description 3
- 102000045576 Lactoperoxidases Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229940057428 lactoperoxidase Drugs 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 235000009518 sodium iodide Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-OIOBTWANSA-N Bromine-77 Chemical compound [77Br] WKBOTKDWSSQWDR-OIOBTWANSA-N 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- GYHNNYVSQQEPJS-OIOBTWANSA-N Gallium-67 Chemical compound [67Ga] GYHNNYVSQQEPJS-OIOBTWANSA-N 0.000 description 1
- GYHNNYVSQQEPJS-YPZZEJLDSA-N Gallium-68 Chemical compound [68Ga] GYHNNYVSQQEPJS-YPZZEJLDSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229940006110 gallium-67 Drugs 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
- 229940055742 indium-111 Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- XMBWDFGMSWQBCA-BJUDXGSMSA-N iodane Chemical compound [126IH] XMBWDFGMSWQBCA-BJUDXGSMSA-N 0.000 description 1
- XMBWDFGMSWQBCA-LZFNBGRKSA-N iodane Chemical compound [133IH] XMBWDFGMSWQBCA-LZFNBGRKSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 229940050929 polyethylene glycol 3350 Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- KJTLSVCANCCWHF-NJFSPNSNSA-N ruthenium-103 Chemical compound [103Ru] KJTLSVCANCCWHF-NJFSPNSNSA-N 0.000 description 1
- KJTLSVCANCCWHF-RNFDNDRNSA-N ruthenium-105 Chemical compound [105Ru] KJTLSVCANCCWHF-RNFDNDRNSA-N 0.000 description 1
- KJTLSVCANCCWHF-AHCXROLUSA-N ruthenium-97 Chemical compound [97Ru] KJTLSVCANCCWHF-AHCXROLUSA-N 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63202787A JPH0272893A (ja) | 1988-08-16 | 1988-08-16 | モノクローナル抗体、その製法およびそれを用いた癌疾患のスクリーニング方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63202787A JPH0272893A (ja) | 1988-08-16 | 1988-08-16 | モノクローナル抗体、その製法およびそれを用いた癌疾患のスクリーニング方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0272893A true JPH0272893A (ja) | 1990-03-13 |
| JPH0466560B2 JPH0466560B2 (enrdf_load_stackoverflow) | 1992-10-23 |
Family
ID=16463186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63202787A Granted JPH0272893A (ja) | 1988-08-16 | 1988-08-16 | モノクローナル抗体、その製法およびそれを用いた癌疾患のスクリーニング方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0272893A (enrdf_load_stackoverflow) |
-
1988
- 1988-08-16 JP JP63202787A patent/JPH0272893A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0466560B2 (enrdf_load_stackoverflow) | 1992-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS60185800A (ja) | モノクロナ−ル抗体 | |
| JP2009149686A (ja) | フィブリンのｄ二量体断片に特異的なｄｄ−３ｂ６／２２から誘導されるヒト化抗体 | |
| JPH04503600A (ja) | 抗インターロイキン―１α及び―１βのモノクローナル抗体、その製法、ならびに前記抗体類の、インターロイキン―１α及び―１βの検出と治療への応用 | |
| KR920002166B1 (ko) | 방사성원소로 레이블된 단일클론항체의 제조방법 | |
| JP2574269B2 (ja) | ヒト前立腺腫瘍関連抗原に対する結合特異性を有するモノクロ−ナル抗体類およびそれらを使用する方法 | |
| JPH0751062B2 (ja) | モノクローナル抗体 | |
| EP0313156B1 (en) | Snrnp-a antigen and fragments thereof | |
| CA1309039C (en) | Monoclonal antibody, process for preparing same, reagent for detecting cancer antigen containing the monoclonal antibody and process for preparing same | |
| EP0506523A2 (en) | Monoclonal antibodies | |
| EP0435185A1 (en) | Anti-human myocardial C protein monoclonal antibody and hybridoma producing the antibody | |
| JPH0272893A (ja) | モノクローナル抗体、その製法およびそれを用いた癌疾患のスクリーニング方法 | |
| EP0205352A2 (en) | Monoclonal anti-human IgG4 antibodies, their production and use | |
| JP4215462B2 (ja) | 非グリコシル化ヘモグロビン、グリコシル化ヘモグロビンに特異的に結合するモノクローナル抗体の製造方法 | |
| JP2792651B2 (ja) | ヒト膵臓癌に対するモノクローナル抗体 | |
| JPH05506241A (ja) | ３５ｋｄ腫瘍関連タンパク質抗原および免疫複合体 | |
| JP3337523B2 (ja) | β−Ｎ−アセチルグルコサミニダ−ゼのサンドイッチ免疫測定法、および該測定法に用いるモノクロ−ナル抗体 | |
| US20100111851A1 (en) | Diagnosis and treatment of cancer by using anti-prg-3 antibody | |
| JP2521496B2 (ja) | 抗ヒト癌モノクロ―ナル抗体 | |
| JPS6378067A (ja) | 癌診断薬 | |
| CN118063610A (zh) | 靶向tim3的抗体及其核素标记物与应用 | |
| JPH058678B2 (enrdf_load_stackoverflow) | ||
| JP3180125B2 (ja) | ヒト成熟骨髄腫細胞に対するモノクローナル抗体 | |
| JPH02219594A (ja) | 肺癌に対するモノクローナル抗体および細胞表面抗原 | |
| Bogoch et al. | Malignin, anti-malignin antibody and scantag | |
| JP2553343B2 (ja) | 癌抗体の測定法 |